[{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"797f38fb-e32f-4728-86c9-79fdb962bf09","acronym":"OBU-BC-II-164","url":"https://clinicaltrials.gov/study/NCT06650748","created_at":"2025-02-25T20:04:34.470Z","updated_at":"2025-02-25T20:04:34.470Z","phase":"Phase 2","brief_title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06650748 - OBU-BC-II-164","lead_sponsor":"Peking University","biomarkers":" CDK4","pipe":"","alterations":" ","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-10-26"},{"id":"2d3dd235-1c39-472f-8f34-e54cae81a145","acronym":"DAWNA-FES","url":"https://clinicaltrials.gov/study/NCT05861830","created_at":"2023-05-17T14:05:14.871Z","updated_at":"2024-07-02T16:35:15.108Z","phase":"Phase 3","brief_title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","source_id_and_acronym":"NCT05861830 - DAWNA-FES","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • tamoxifen • capecitabine • fulvestrant • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-12"},{"id":"389ebfec-96d0-4ae7-9d59-0a96b42cf326","acronym":"","url":"https://clinicaltrials.gov/study/NCT06208410","created_at":"2024-01-17T18:20:05.757Z","updated_at":"2024-07-02T16:35:15.660Z","phase":"Phase 1/2","brief_title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","source_id_and_acronym":"NCT06208410","lead_sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi) • capecitabine • Irene (pyrotinib) • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 01/11/2024","start_date":" 01/11/2024","primary_txt":" Primary completion: 02/26/2026","primary_completion_date":" 02/26/2026","study_txt":" Completion: 02/26/2026","study_completion_date":" 02/26/2026","last_update_posted":"2024-03-08"},{"id":"dd28d993-6600-4867-be5c-e4c5b6a3530d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05574881","created_at":"2022-10-12T13:56:29.617Z","updated_at":"2025-02-25T12:29:06.657Z","phase":"Phase 1/2","brief_title":"Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05574881","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • fulvestrant • AiRuiKang (dalpiciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-26"},{"id":"60298b72-be6e-47b1-836c-a8eab3554461","acronym":"BCTOP-L-M01","url":"https://clinicaltrials.gov/study/NCT05949541","created_at":"2023-07-20T15:09:16.077Z","updated_at":"2024-07-02T16:35:20.123Z","phase":"Phase 2","brief_title":"Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer","source_id_and_acronym":"NCT05949541 - BCTOP-L-M01","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • exemestane • AiRuiKang (dalpiciclib) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-02-08"},{"id":"a12b006f-dc84-4bc8-80cc-7523ed0f98b1","acronym":"ENIGMA","url":"https://clinicaltrials.gov/study/NCT05205200","created_at":"2022-01-25T16:54:16.056Z","updated_at":"2024-07-02T16:35:20.272Z","phase":"Phase 2","brief_title":"Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02","source_id_and_acronym":"NCT05205200 - ENIGMA","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR • SMARCA2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR • SMARCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • fulvestrant • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 06/06/2022","start_date":" 06/06/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-02-08"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"8f51155f-9935-4d7a-a804-14d327bef42c","acronym":"BCTOP-L-M04","url":"https://clinicaltrials.gov/study/NCT05759572","created_at":"2023-03-08T17:01:38.073Z","updated_at":"2024-07-02T16:35:20.712Z","phase":"Phase 2","brief_title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT05759572 - BCTOP-L-M04","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • fulvestrant • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-06"},{"id":"faab4dbf-7eb8-4669-87ff-4f8160e576b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05759546","created_at":"2023-03-08T17:01:37.605Z","updated_at":"2024-07-02T16:35:20.716Z","phase":"Phase 2","brief_title":"PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer","source_id_and_acronym":"NCT05759546","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-06"},{"id":"898bb64f-c295-48d3-b8db-c46b13970a53","acronym":"DANCER","url":"https://clinicaltrials.gov/study/NCT05640778","created_at":"2022-12-07T15:57:13.683Z","updated_at":"2024-07-02T16:35:21.550Z","phase":"Phase 2","brief_title":"Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)","source_id_and_acronym":"NCT05640778 - DANCER","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-01-31"},{"id":"02eaa568-b3ce-4a18-a3ca-9ab426a744ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05132790","created_at":"2021-11-24T18:55:39.081Z","updated_at":"2024-07-02T16:35:24.664Z","phase":"","brief_title":"Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment","source_id_and_acronym":"NCT05132790","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • albumin-bound paclitaxel • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-03"},{"id":"b4f9c583-fb68-430d-9978-7993ca7e88fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03481998","created_at":"2021-01-18T17:09:17.031Z","updated_at":"2024-07-02T16:35:28.529Z","phase":"Phase 1/2","brief_title":"A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT03481998","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • AiRuiKang (dalpiciclib)"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 07/30/2022","primary_completion_date":" 07/30/2022","study_txt":" Completion: 07/30/2022","study_completion_date":" 07/30/2022","last_update_posted":"2023-11-21"},{"id":"2a514802-0bd5-42d1-abc9-294d1a4f3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT06133088","created_at":"2023-11-15T19:16:06.349Z","updated_at":"2024-07-02T16:35:29.099Z","phase":"Phase 2","brief_title":"Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.","source_id_and_acronym":"NCT06133088","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" CDK6 • LRPPRC","pipe":"","alterations":" ","tags":["CDK6 • LRPPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • R-(-)-gossypol (AT 101)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-11-15"},{"id":"a51ab208-1f88-4770-b202-ff231237ef10","acronym":"","url":"https://clinicaltrials.gov/study/NCT06107673","created_at":"2023-10-30T16:12:57.974Z","updated_at":"2024-07-02T16:35:31.180Z","phase":"Phase 2","brief_title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","source_id_and_acronym":"NCT06107673","lead_sponsor":"Hebei Medical University Fourth Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • epirubicin • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-30"},{"id":"ab67aa4e-3706-4bb1-9ddb-654da25dc17d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05328440","created_at":"2022-04-14T11:53:41.939Z","updated_at":"2024-07-02T16:35:35.894Z","phase":"Phase 2","brief_title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","source_id_and_acronym":"NCT05328440","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • EGFR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib) • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-09-25"},{"id":"ed8fa678-ab4b-48fa-9087-5a8721ebadce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05979220","created_at":"2023-08-07T14:08:58.570Z","updated_at":"2024-07-02T16:35:40.831Z","phase":"Phase 2","brief_title":"Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy","source_id_and_acronym":"NCT05979220","lead_sponsor":"Shuangyue Liu","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-08-07"},{"id":"a5bccc88-2f23-45d3-a1c1-0cbe2b9575bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952128","created_at":"2023-07-20T14:08:48.213Z","updated_at":"2024-07-02T16:35:42.594Z","phase":"Phase 2","brief_title":"Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma","source_id_and_acronym":"NCT05952128","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-19"},{"id":"7faf4bf2-53b0-497d-b728-8a343862386e","acronym":"DAP-Her-01","url":"https://clinicaltrials.gov/study/NCT04293276","created_at":"2021-01-18T20:49:56.891Z","updated_at":"2024-07-02T16:35:48.954Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer","source_id_and_acronym":"NCT04293276 - DAP-Her-01","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • AiRuiKang (dalpiciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 08/23/2021","primary_completion_date":" 08/23/2021","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2023-05-04"},{"id":"c8c01e6c-2733-4dd5-8269-1c7a962b4b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176080","created_at":"2022-01-04T14:54:23.045Z","updated_at":"2024-07-02T16:35:49.000Z","phase":"Phase 1/2","brief_title":"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT05176080","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2023-05-04"},{"id":"099db88d-b313-480f-a32a-795f6358c12a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836520","created_at":"2021-04-08T13:52:43.973Z","updated_at":"2024-07-02T16:35:50.873Z","phase":"Phase 2","brief_title":"SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.","source_id_and_acronym":"NCT04836520","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • AiRuiKang (dalpiciclib)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-04-12"},{"id":"7e4f81a6-72f5-4f86-a545-a5378d007797","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463601","created_at":"2022-07-19T15:55:10.839Z","updated_at":"2024-07-02T16:35:50.729Z","phase":"Phase 2","brief_title":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","source_id_and_acronym":"NCT05463601","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • HHPG-19K (mecapegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-12"},{"id":"9d718a4a-a280-403f-8c25-776772ff621b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04733417","created_at":"2021-02-02T15:52:07.038Z","updated_at":"2024-07-02T16:35:50.733Z","phase":"Phase 2","brief_title":"A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.","source_id_and_acronym":"NCT04733417","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib) • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-04-12"},{"id":"0d45d6d8-d81d-499e-8692-bfb09404a4d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05806671","created_at":"2023-04-10T14:03:18.818Z","updated_at":"2024-07-02T16:35:51.010Z","phase":"Phase 2","brief_title":"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy","source_id_and_acronym":"NCT05806671","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-04-10"}]